# OnCo record avencell-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/avencell-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "avencell-therapeutics" ;
  schema:name "AvenCell Therapeutics"@en ;
  schema:description "AvenCell Therapeutics makes CAR-T cell therapies that can be switched on and off after they are given, including ready-made versions from donor cells. It is testing them in acute myeloid leukaemia and in B-cell lymphomas."@en ;
  schema:url <https://onco.cc/companies/avencell-therapeutics/>, <https://avencell.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://avencell.com/>, <https://avencell.com/avencell-raises-112-million-in-series-b-funding-led-by-novo-holdings/>, <https://avencell.com/avencell-therapeutics-announces-first-patient-dosed-in-phase-i-quadvance-study-with-avc-203-a-novel-allogeneic-cd19-cd20-dual-targeting-car-t-investigational-therapy-for-the-treatment-of-relapsed-ref/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/armored-car/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd123/> ;
  onco:trials <https://onco.cc/trials/nct07284433/> .